• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Continuous antioxidant drug exposure: a bridge from ideal world to real world of therapy for amyotrophic lateral sclerosis.

作者信息

Wang Jun, Zhou Xin-Fu, Wang Yan-Jiang

机构信息

Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing 400042, China.

Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing 400042, China.

出版信息

Life Med. 2022 Oct 8;2(1):lnac042. doi: 10.1093/lifemedi/lnac042. eCollection 2023 Feb.

DOI:10.1093/lifemedi/lnac042
PMID:39872952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11749702/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe2a/11749702/fd10a156f37c/lnac042_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe2a/11749702/fd10a156f37c/lnac042_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe2a/11749702/fd10a156f37c/lnac042_fig1.jpg

相似文献

1
Continuous antioxidant drug exposure: a bridge from ideal world to real world of therapy for amyotrophic lateral sclerosis.持续抗氧化药物暴露：从肌萎缩侧索硬化症治疗的理想世界到现实世界的一座桥梁。
Life Med. 2022 Oct 8;2(1):lnac042. doi: 10.1093/lifemedi/lnac042. eCollection 2023 Feb.
2
A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease.肌萎缩侧索硬化症/运动神经元病抗氧化治疗的系统评价
Amyotroph Lateral Scler. 2008 Aug;9(4):195-211. doi: 10.1080/17482960801900032.
3
Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease.肌萎缩侧索硬化症/运动神经元病的抗氧化治疗
Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD002829. doi: 10.1002/14651858.CD002829.pub4.
4
TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients.肌萎缩侧索硬化症和额颞叶痴呆患者脑脊液中TDP - 43实时震颤诱导转化反应的优化及种子活性检测
Brain Commun. 2020 Sep 14;2(2):fcaa142. doi: 10.1093/braincomms/fcaa142. eCollection 2020.
5
Limited value of serum neurofilament light chain in diagnosing amyotrophic lateral sclerosis.血清神经丝轻链在诊断肌萎缩侧索硬化症中的价值有限。
Brain Commun. 2023 May 19;5(3):fcad163. doi: 10.1093/braincomms/fcad163. eCollection 2023.
6
El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors.世界神经病学联合会埃斯科里亚尔肌萎缩侧索硬化诊断标准。世界神经病学联合会神经肌肉疾病研究组运动神经元疾病/肌萎缩侧索硬化小组委员会以及埃斯科里亚尔“肌萎缩侧索硬化的临床界限”研讨会参与者。
J Neurol Sci. 1994 Jul;124 Suppl:96-107. doi: 10.1016/0022-510x(94)90191-0.
7
Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease.肌萎缩侧索硬化症/运动神经元病的抗氧化治疗
Cochrane Database Syst Rev. 2005 Jan 25(1):CD002829. doi: 10.1002/14651858.CD002829.pub3.
8
Antioxidant treatment for amyotrophic lateral sclerosis / motor neuron disease.肌萎缩侧索硬化症/运动神经元病的抗氧化治疗
Cochrane Database Syst Rev. 2004 Oct 18(4):CD002829. doi: 10.1002/14651858.CD002829.pub2.
9
Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study.一项使用真实世界数据评估波舒替尼治疗肌萎缩侧索硬化症的 2 期研究方案：肌萎缩侧索硬化症药物再利用的诱导多能干细胞研究（iDReAM 研究）。
BMJ Open. 2024 Oct 26;14(10):e082142. doi: 10.1136/bmjopen-2023-082142.
10
The Role of Ferroptosis in Amyotrophic Lateral Sclerosis Treatment.铁死亡在肌萎缩侧索硬化症治疗中的作用。
Neurochem Res. 2024 Oct;49(10):2653-2667. doi: 10.1007/s11064-024-04194-w. Epub 2024 Jun 12.

本文引用的文献

1
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.依达拉奉静脉输注治疗肌萎缩侧索硬化症的长期安全性和有效性。
JAMA Neurol. 2022 Feb 1;79(2):121-130. doi: 10.1001/jamaneurol.2021.4893.
2
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.依达拉奉在明确诊断的肌萎缩侧索硬化症患者中的安全性和有效性：一项随机、双盲、安慰剂对照试验。
Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15.
3
Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits.
依达拉奉可减轻阿尔茨海默病型病理变化和认知缺陷。
Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5225-30. doi: 10.1073/pnas.1422998112. Epub 2015 Apr 6.
4
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.依达拉奉（MCI-186）治疗肌萎缩侧索硬化症患者疗效与安全性的验证性双盲、平行组、安慰剂对照研究。
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7. doi: 10.3109/21678421.2014.959024. Epub 2014 Oct 6.
5
Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis.散发性和家族性肌萎缩侧索硬化症中氧化损伤增加的证据。
J Neurochem. 1997 Nov;69(5):2064-74. doi: 10.1046/j.1471-4159.1997.69052064.x.